Here is some important info, and good news, for kids with leukemia that have relapsed from here at ASH:
ASH: Regimen Ups Survival in Relapsed ALL in Kids
By Charles Bankhead, Staff Writer, MedPage Today
ORLANDO — Children with relapsed acute lymphoblastic leukemia (ALL) had significantly better progression-free and overall survival when treated with induction therapy containing mitoxantrone versus that containing idarubicin, data from an open-label randomized trial showed.
Three-year overall survival with mitoxantrone was 69% compared with 45.2% with idarubicin. The mitoxantrone group had similar improvement in progression-free survival (PFS), Catriona Parker, MD, reported here at the American Society of Hematology meeting.
The findings suggest that conventional therapies for childhood ALL warrant more consideration before moving on to newer drugs.
I couldn’t have written it better myself! Charles does a great job with this. Read the entire article by going to: Medical News – 20% survival advantage for kids with relapsed leukemia.
A good way to open ASH, don’t you think? Any day someone finds a way for kids with cancer to live longer is a good day!
Feel good and keep smiling! Pat